Germany Archives

News and Trends 5 Mar 2015

Baxter’s Bioscience Business Acquires SuppreMol

Baxter has acquired SuppreMol for €200M before working capital and other adjustments. The acquisition includes SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases, focusing on the modulation of Fc […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant

Boehringer Ingelheim submitted idarucizumab for approval of marketing authorization to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canada. The submission is directed to patients who require rapid reversal of the anticoagulant effect of dabigatran, the active ingredient in Boehringer Ingelheim’s Pradaxa. Pradaxa, a direct thrombin inhibitor (DTI), was the first […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Feb 2015

Is Pichia Pastoris the Best Protein Expression System?

Producing biologicals in living expression systems is a big challenge for the Biotech industry. World leaders in the field are betting on a new yield-enhancing expression technology using the yeast Pichia pastoris. Escherichia coli might be the first bacteria you think about when it comes to biotechnology. However, E. coli is not necessarily the best option to produce […]

February 10, 2015 - 4 minutesmins - By Lourdes Riquelme

News and Trends 3 Feb 2015

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

New agreement was signed between AYOXXA, an international biotech company with headquarters in Cologne, and the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic […]

February 3, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 1 Feb 2015

Phenex sells out its main programme to Gilead

Gilead Sciences announces the acquisition of Phenex Pharmaceuticals’ development program for non-alcoholic steatohepatitis (NASH) and other liver diseases. Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including non-alcoholic steatohepatitis […]

February 1, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 20 Jan 2015

Will Microalgaes solve the Rare Earth conflict?

The extraction of rare earths is a very expensive process, having dramatic consequences for the planet (degradation, impacts on water quality, etc.). Currently, China controls 95% of the World production of these minerals widely used in the field of new technologies and electronics. The development of new methods of sustainable recycling from waste and environmentally friendly is […]

January 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jan 2015

Qiagen, the new giant in next-gen sequencing tools?

Yet again, a new acquisition in this beginning of 2015. Enzymatics, the Boston-area based Biotech company and leading provider of enzymes for Next-gen sequencing, has been acquired by Qiagen for a non-disclosed amount. The amount must be pretty high since Enzymatics’ enzymes are used in 80% of all NGS reactions and the company counts over 150 employees. […]

January 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Dec 2014

Promising Agreement Signed for Regenerative Medicine

Heraeus Medical signed an agreement with Locate Therapeutics to license the intellectual property surrounding the use of TAOS in orthopaedic applications and the inception of the first development program in this field. The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. […]

December 10, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 1 Dec 2014

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

What could you buy with €1,1M euros? A house? Or a single prescription for a new drug… The first gene therapy drug “Glybera” is set to go on sale in Germany with a €1.1 million price tag, a new record for a medicine to treat a rare disease. And this drug from UniQure is not the only one […]

December 1, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 28 Nov 2014

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Oxford BioTherapeutics and Menarini Group have initiated the first-in-human clinical study of OBT357, a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five development programs between the two companies to enter the clinic in a $1 billion strategic oncology alliance. Oxford BioTherapeutics and the Menarini Group established their […]

November 28, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 27 Nov 2014

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat […]

November 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Nov 2014

Munich: Why is it One of the Best Biotech Cluster in Europe ?

The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich’s status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study carried out by the City of Munich, the IHK and BioM based […]

November 23, 2014 - 3 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

Baxter’s Bioscience Business Acquires SuppreMol

Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant

Is Pichia Pastoris the Best Protein Expression System?

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

Phenex sells out its main programme to Gilead

Will Microalgaes solve the Rare Earth conflict?

Qiagen, the new giant in next-gen sequencing tools?

Promising Agreement Signed for Regenerative Medicine

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Munich: Why is it One of the Best Biotech Cluster in Europe ?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!